Ipraxa

Ipratropium bromide, the active ingredient in Ipraxa, is an anticholinergic bronchodilator presented as an inhalation solution for inhalation use. It is employed to manage airway obstruction in chronic obstructive pulmonary disease and asthma, providing symptom relief and improving lung function.

GNH USA supplies Ipraxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipraxa is an anticholinergic bronchodilator indicated for diseases affecting the lower respiratory tract.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces the frequency of exacerbations. - Asthma: provides bronchodilation as an add‑on therapy for patients with reversible airway obstruction. - Bronchospasm: relieves acute bronchospasm associated with COPD or asthma episodes.

Adverse reactions may occur with inhaled ipratropium bromide.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough: irritation of the airway. - Throat irritation: mild soreness after inhalation. - Headache: transient discomfort. - Dizziness: occasional light‑headedness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway narrowing. - Angioedema: swelling of face, lips, or tongue. - Severe allergic reaction: rash, itching, or anaphylaxis. - Urinary retention: difficulty emptying the bladder. - Tachycardia: rapid heart rate. - Acute glaucoma: increased intra‑ocular pressure.

Before initiating therapy, consider the following precautions.

- Assess renal function: use with caution in patients with severe renal impairment. - Monitor anticholinergic load: watch for dry mouth, constipation, or blurred vision. - Avoid in narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Use cautiously in urinary retention or prostate hypertrophy: may worsen symptoms. - Store at room temperature: keep in the original container, protect from moisture and light.

Ipratropium bromide may interact with other medications.

Major Interactions (Avoid): - Concurrent anticholinergic inhalers: increased anticholinergic burden. - Beta‑agonists: may mask bronchospasm symptoms. - MAO inhibitors: potential for hypertensive reactions (rare).

Moderate Interactions (Monitor Closely): - Antihistamines: additive drying of secretions. - Tricyclic antidepressants: heightened anticholinergic side effects. - Theophylline: monitor for additive bronchodilator effect.